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Behc ¸et’s syndrome (BS) is a relapsing, chronic, inﬂammatory disease characterized by endothelial dysfunction, atherothromboem-
bogenesis,andleukocytoclasticvasculitiswithcompleximmunologicmolecularinteractions.Generalizedderangementsofthelym-
phocyte and neutrophil populations, activated monocytes, and increased PMNLs motility with upregulated cell surface molecules
such as ICAM-1, VCAM-1, and E-selectin, which are found on the endothelial cells, leukocytes, and platelets, have all been demon-
strated during the course of BS. Our aim is to investigate the association of serum concentrations of soluble P-selectin in patients
with BS, and to evaluate whether disease activity has an eﬀect on their blood levels. This multicenter study included 31 patients
with BS (15 men and 16 women) and 20 age- and sex-matched healthy control volunteers (11 men and nine women). Neutrophil
count, erythrocyte sedimentation rate, and acute-phase reactants as well as soluble P-selectin levels were determined. The mean
age and sex distributions were similar (P>. 05) between BS patients (35 years) and control volunteers (36 years). Serum levels of
soluble P-selectin in patients with BS (399 ± 72ng/mL) were signiﬁcantly (P<. 001) higher when compared with control subjects
(164 ± 40ng/mL). In addition, active BS patients (453 ± 37ng/mL) had signiﬁcantly (P<. 001) elevated levels of soluble P-selectin
than those in inactive period (341 ± 52ng/mL). This study clearly demonstrated that serum soluble P-selectin levels are increased
in BS patients when compared with control subjects, suggesting a modulator role for soluble P-selectin during the course of platelet
activation and therefore, atherothrombogenesis formation in BS, especially in active disease.
INTRODUCTION
Behc ¸et’s syndrome (BS) is a chronic and inﬂamma-
tory disease which involves multiple organs with a gener-
alized vasculitis of arteries and veins [1]. This chronic dis-
ease was ﬁrst described by Hulusi Behc ¸et in 1937 [2]. Oral
apthae, genital ulcers, and ocular involvement mainly as
uveitis are the classical signs of the disease. However, ev-
eryorganinthebodycouldbeaﬀectedbyBS[1,3,4,5,6].
TheprevalenceofBSisashighas1/1000inMediterranean
(Turkey) and Middle and Far East countries (Japan)
[7, 8, 9].Althoughthereisnoprovencausativeagent,viral
infections, immune disorders, genetic predisposition, and
environmental factors have been proposed as etiologic
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factors [7]. Endothelial dysfunction causes vasculitis and
thrombosis in BS [10]. International Study Group have
deﬁned the criterion for the diagnosis of BS in 1990 [11].
Major challenge in the management of patients with BS is
lack of clear notion of etiopathogenesis. Moreover, thera-
peutic approaches are based on assumptions rather than
proven mechanisms of the disease.
Selectins are found on endothelial cells, leukocytes,
and platelets [12]. There are three types of selectins,
namely, E-, L-, and P-selectins [13] .T h e s ec e l ls u r f a c e
glycoproteins are thought to promote inﬂammatory reac-
tions by facilitating leukocyte recruitment [14]. Activated
platelets express P-selectin, which binds to P-selectin
glycoprotein ligand 1 (PSGL-1). This interaction is re-
sponsible for the recruitment of inﬂammatory leukocytes
to thrombi [15].
Because of its impacts on endothelial cells with its ef-
fect on leukocytes, we aimed to investigate serum levels of
solubleP-selectinduring thecourseofBS.Ourhypothesis238 Yusuf Turkoz et al 2005:4 (2005)
is that soluble P-selectin could be important during the
inﬂammatory process of the disease course. Therefore,
the aims of this study were (1) to investigate the associ-
ation of serum soluble P-selectin concentrations in pa-
tients with BS and (2) to evaluate whether disease activity
has an eﬀect on the blood soluble P-selectin concentra-
tion.
PATIENTS AND METHODS
This multicenter study included 31 patients with
Behc ¸et’s syndrome and 20 age- and sex-matched healthy
controlvolunteers.Subjectswithhepaticorrenaldiseases,
diabetes,essentialhypertension,andpregnancieswereex-
cluded from the study. Detailed history of drugs used was
obtained in both groups. The diagnosis of uveitis was
made according to the International Study Group criteria
[16] and informed consent was obtained from all subjects
in both groups.
Both clinical and laboratory ﬁndings were used to de-
termine disease activity. Clinically, worsening of clinical
symptoms on admission with having at least two of the 5
majorsymptomsaccordingtotheISGcriteriawasconsid-
ered to be in the exacerbation stageof the disease. Inactive
patients had no symptoms or signs of disease activity at
least two months before admission. In laboratory investi-
gations, ESR, neutrophil count, and acute-phase reactants
were investigated [17, 18].
Neutrophilcount,ESR,andacute-phasereactants
analyses
In all subjects, antecubital whole blood samples (total
5mL) were obtained by venipuncture from an antecubital
vein, avoiding haemolysis, into plain tubes during resting
position after an overnight fast and 30 minutes of supine
rest.Noneofthesubjectsinbothgroupswasreceivingany
topical or systemic medication on admission. Both the
technician taking the blood and the analyser were blinded
tothegroupofthesubject.Theﬁrsthalfofthebloodsam-
ples (2.5mL) was centrifuged at 800 x gravity for 10 min-
utes, and then serum was separated and kept at −70◦C
until time of analysis.
Second half of the blood samples (2.5mL) with
EDTA (1mg/mL) anticoagulant was used for the neu-
trophil counting by an automated blood counter
(Coulter-STKS, Luton, UK). α1-antitrypsin and α2-
macroglobulin concentrations were measured in the
serum by Behring nephelometer 100 analyser. The ESR
was determined by the classical Westergren method [19,
20, 21].
SolubleP-selectinanalysis
Blood samples were taken by venopuncture from
the patients with BS and 20 healthy individuals and al-
lowed to clot for 15 minutes on ice before centrifuga-
t i o na n ds e r u mw a ss t o r e da t−40◦C until analysis. Hu-
man serum P-selectin levels were measured by soluble
P-selectin enzyme-linked immunosorbent assay kit (Ben-
der MedSystems, Vienna, Austria). ELISA assay was car-
ried out on diluted samples following manufacturer’s in-
structions. Assay range of the sP-selectin kit was 1–140ng
sP-selectin/mL and minimal detection limit was approx-
imately 1.0ng/mL. The intraassay and interassay coeﬃ-
cients of variation for the assay were 5% and 8%, respec-
tively.
Statisticalanalysis
The Mann-Whitney U test was used for analysis and
the results were expressed as mean ± SD with range. Sta-
tistical Package for the Social Sciences for Windows (SPSS
Inc., version8.0,Chicago,Ill,USA)wasusedforstatistical
analysis and P<. 05 was considered to be signiﬁcant.
RESULTS
Behc ¸et’s syndrome patients were consisted of 15 men
a n d1 6w o m e n( m e a na g e= 35 years) and there were 11
men and 9 women in the age- and sex-matched healthy
control volunteers (mean age = 36 years). Oral aph-
thae were present in all cases (100%). Seventeen patients
(54.8%) had bilateral ocular disease (anterior hypopyon
uveitis, iridocyclitis, retinal vasculitis, vitritis, or panu-
veitis). Twenty-nine cases (93.5%) had various skin le-
sions,27patients(87.0%)hadarticularsymptoms,and24
patients (77.4%) had genital ulcers. Sixteen cases (51.6%)
demonstrated positive pathergy test. Gastrointestinal sys-
tem symptoms were present in 4 cases (12.9%) and neu-
rological disease in 1 case (0.3%).
The mean disease duration for Behc ¸et’s patients was
10 years. The diﬀerences for the ages between the groups
were similar (for each group, P>. 05). Active patients had
signiﬁcantly higher values for acute-phase reactants when
compared with inactive patients and control volunteers
(for each, P<. 01) (see Table 1). Serum levels of soluble
P-selectin in patients with BS (399 ± 72ng/mL) were sig-
niﬁcantly (P<. 001) higher when compared with control
subjects (164 ±40ng/mL). In addition, active BS patients
(453 ± 37ng/mL) had signiﬁcantly (P<. 001) elevated
levels of soluble P-selectin than those in inactive period
(341 ±52ng/mL) of the disease (see Figure 1).
DISCUSSION
Selectins are adhesion molecules regulating interac-
tions of the leukocytes, platelets, and endothelial cells
[13]. These molecules are involved in leukocyte migra-
tion and inﬂammation by regulating the interactions
of the leukocytes with endothelium, which are essential
components of the immune response [22]. Circulating
leukocytes bind to the selectins expressed by activated en-
dothelium and thereby leukocyte migration occurs [23].
On the other hand, selectins are molecules involved in
chronic and acute inﬂammation process. They are found2005:4 (2005) Soluble P-Selectin in Behc ¸et’s Syndrome 239
Table 1. The levels of acute-phase reactants in patients with active or inactive patients with Behc ¸et’s syndrome and healthy control
volunteers. (BS denotes Behc ¸et’s syndrome.)
Active BS Inactive BS Controls
(n = 16) (n = 15) (n = 20)
Mean ± SD Mean ± SD Mean ± SD
Mean age (years) 35 ± 11 34 ± 10 36 ± 9
Soluble P-selectin (ng/mL) 453 ±37∗ 341 ±52† 164 ±40
Neutrophil count (×103/mL) 5 ±1∗ 3 ±0.63 ±0.3
Erythrocyte sedimentation rate (mm/1 h) 35 ±7∗ 22 ±6† 9 ±1
α1-antitrypsin (mg/dL) 208 ±56∗ 164 ±49† 134 ±18
α2-macroglobulin (mg/dL) 269 ±31∗ 211 ±23† 158 ±25
∗Signiﬁcantly diﬀerent from the inactive patients and controls by Mann-Whitney U test (for each, P<. 01).
†Signiﬁcantly diﬀerent from the controls by Mann-Whitney U test (for each, P<. 01).
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Figure 1. The distribution of serum sP-selectin levels against
disease activity in patients with active BS and inactive BS.
to be eﬀective in postischemic inﬂammation in mus-
cle, kidney, and heart, skin inﬂammation, atherosclero-
sis, glomerulonephritis, and luphus erythematosus [12].
Themajorroleofinﬂammationinatherosclerosishasfor-
warded researchers to investigate selectin levels in coro-
nary syndromes. Soluble P-selectin was shown to increase
in patients with unstable angina and myocardial infarc-
tion [24, 25, 26]. Elevated levels of soluble P-selectin have
been reported in pulmonary arterial hypertension [27],
chronic heart failure [28], and cyanotic congenital heart
disease [29] as well. Concerning the role of soluble P-
selectin in rheumatological diseases, Ates ¸e ta l[ 30]h a v e
reported that serum soluble P-selectin levels were not
signiﬁcantly diﬀerent among patients with rheumatoid
arthritis and systemic sclerosis.
Becausethereisnotanydeﬁnitiveandspeciﬁctherapy
of BS [31, 32] and it aﬀects every organ in the body with
no exceptions [1, 3, 4, 5, 6], there is probably a molecule
or a group of molecules aﬀecting the human body in gen-
eral. In addition, these molecules could start a generalized
inﬂammation in BS patients. Moreover, these molecules
taking part in the etiopathogenesis of BS should have the
potential eﬀect of causing venous thrombosis. Endothe-
lial dysfunction is the most prominent feature of BS and
is observed even in patients without any clinical vascular
involvement[33,34,35].ThepathogenesisofBSisclosely
related to endothelial cells, leukocyte functions, and au-
toimmunity, and previous studies have investigated se-
lectin adhesion molecules (P- and E-selectin) in the cir-
culation [36]. It has been demonstrated that all of the ad-
hesion molecules were increased in serum from patients
withBScomparedwithcontrols.Inaddition,serumlevels
ofE-selectinwereprominentlyincreasedduringtheactive
stage of the disease, indicating the presence of immune
system activation and endothelial injury in BS [37]. Fur-
thermore, the expression of E- and L- selectin on the en-
dothelial and inﬂammatory cells by immunohistochem-
istry in erythema nodosum lesions taken from 15 patients
with BS has been demonstrated previously [38].
In the present study, we aimed to investigate serum
soluble P-selectin concentrations in patients with BS and
to evaluate the relation of serum soluble P-selectin lev-
els with disease activity. We demonstrated (1) an increase
in serum soluble P-selectin levels in patients with BS and
(2) increased concentrations of soluble P-selectin levels
in patients with active BS. Depending on these results, it
is possible that soluble P-selectin may take a role in the
pathophysiologyofvascularlesions,andthereforeinﬂam-
matoryreactionsbyfacilitatingleukocyterecruitment.An
association of soluble P-selectin with proinﬂammatory
cytokines can be suggested, as increased levels of soluble
P-selectin is correlated with the activity of BS.
P-, E-, and L-selectins are members of the selectin ad-
hesion molecule family [13]. E-selectin is expressed by ac-
tivated endothelial cells. P-selectin is constitutively syn-
thesized and stored within the granules of platelets and240 Yusuf Turkoz et al 2005:4 (2005)
is redistributed to the plasma membrane upon activa-
tion of these cells. L-selectin, however, is expressed on
the leukocyte surface. These adhesion molecules can be
usedasactivationmarkersofendothelium(E-selectinand
possibly P-selectin), platelets (P-selectin), and leukocytes
(L-selectin). The main role of these adhesion molecules
is closely related to the immunological response of the
regulation of leukocyte traﬃcking. P-selectin also has ad-
ditional speciﬁc roles in the inﬂammatory and homeo-
static functions of the platelets [13]. The characteristic
pathological ﬁnding is a multifocal necrotizing vasculitis
with lymphotic inﬁltration of the veins, capillaries, and
arteries. Up to 25% of BS patients suﬀer from systemic
venous thrombosis [3, 39]. In the light of this knowl-
edge, soluble P-selectin may participate during the course
of inﬂammatory and thrombotic vasculitis events during
the course of BS because an activated hemostatic system
with an increased arterial and venous thrombotic ten-
dency are among the clinical features of BD. In the previ-
ous studies on the levels of selectins in BS, Haznedaroglu
et al [36] have reported that more prominent increases
in selectin levels in patients with extensive BS suggest
that circulating selectin concentrations are related to dis-
ease severity [36]. In contrast, Nagahama et al [40]h a v e
found no elevations for sP-selectin levels in patients with
BS.
In conclusion, this study clearly demonstrated that
serumsolubleP-selectinlevelsareincreasedinBSpatients
when compared with control subjects, suggesting a mod-
ulator role of soluble P-selectin in BS. In addition, pa-
tients with active BS had signiﬁcantly higher serum sol-
uble P-selectin levels than remaining BS patients. There-
fore, serum levels of soluble P-selectin may provide a use-
ful marker for vascular inﬂammatory diseases and may
possibly be used for both diagnosis and estimation of dis-
ease activity in BS patients.
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